| Biomarker ID | 583 |
| PMID | 21240253 |
| Year | 2010 |
| Biomarker | β-microseminoprotein (MSMB) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | increased expression with decreased biochemical recurrence-free survival |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate Analysis: HR: 0.468; (95% CI: 0.394-0.556); Multivariate Analysis: HR: 0.710 (95% CI :0.578-0.872); |
| Effect on Pathways | Oncostatin M |
| Experiment | Biochemical Recurrence Vs No Biochemical Recurrence |
| Type of Biomarker | Prognostic |
| Cohort | Tissue specimens were available from 3268 patients, undergoing radical prostatectomy were taken. Full follow-up data were available for 2460 patients, of which 620 developed biochemical recurrence. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | Univariate Analysis; Biochemical recurrence was defined as post-operative PSA values of >=0.1ng/ ml with a confirmatory value. |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | MSMB |